Shetty Kiran, Shetty Ranjan, Bairy Lakshminarayana, Rao Pragna, Kiran Amruth, Shetty Manjunath, Nayak Vidya
Research Scholar, Department of Cardiology, KMC, Manipal University, Manipal, Karnataka, India.
Professor, Department of Cardiology, KMC, Manipal University, Manipal, Karnataka, India.
J Clin Diagn Res. 2017 May;11(5):FC01-FC05. doi: 10.7860/JCDR/2017/23825.9763. Epub 2017 May 1.
Hypertension is a major health issue worldwide. Calcium Channel Blockers (CCBs) are the most commonly used antihypertensive agents. CCBs act on voltage-dependent calcium channels and they were categorized into two subclasses, Dihydropyridine (DHP) and non-Dihydropyridine (non-DHP) derivative. Amlodipine is a third generation L-type of DHP and Cilnidipine is a novel L/N-type of DHP CCB, both drugs have excellent pharmacological profiles with the unique actions.
To study the clinical and biochemical profile in Amlodipine and Cilnidipine treated mild to moderate hypertensive patients.
The present study was a cross-sectional study. A total of 140 mild to moderate hypertensive patients (HTN classified according to Joint National Committee-8 (JNC-8) HTN guideline), 70 were in Amlodipine group (Group-A), and other 70 patients were in Cilnidipine group (Group-B). Group-A receiving Tab Amlodac 5 mg/day and Group-B receiving Tab Cilacar 10 mg/day, and both the group receiving respective medications since more than six months. Patients enrolled into the study with due consideration of eligibility criteria. Demographic, clinical and biochemical parameters were noted and compared.
Demographic parameters are matched, there was no significant difference seen between two study groups. Systolic and Diastolic Blood Pressure (SBP and DBP) showed a significant difference (p<0.001). There was no significant difference in pulse rate between the two groups, both QT/QTc showed statistically significant difference (p<0.001). The biochemical parameters like serum creatinine, albumin, globulin, total protein, serum Na, fractional excretion of Na, serum osmolality, vanillyl mandelic acid, were compared between two study groups, there was no significant difference seen between the two groups.
The Amlodipine and Cilnidipine both are equally effective antihypertensive drugs. Cilnidipine treated group showed more reduction in blood pressure than the Amlodipine treated group and there was no significant change in heart rate between the two groups. Cilnidipine group showed comparatively shortened QT/QTc interval than the Amlodipine group.
高血压是全球主要的健康问题。钙通道阻滞剂（CCB）是最常用的抗高血压药物。CCB作用于电压依赖性钙通道，可分为两个亚类，即二氢吡啶类（DHP）和非二氢吡啶类（非DHP）衍生物。氨氯地平是第三代L型DHP，西尼地平是新型L/N型DHP CCB，这两种药物均具有出色的药理特性和独特作用。
研究氨氯地平和西尼地平治疗轻度至中度高血压患者的临床和生化特征。
本研究为横断面研究。共有140例轻度至中度高血压患者（根据美国国家联合委员会第8版（JNC-8）高血压指南分类），70例在氨氯地平组（A组），另外70例患者在西尼地平组（B组）。A组服用氨氯地平片5毫克/天，B组服用西尼地平片10毫克/天，两组均服用各自药物超过六个月。纳入研究的患者充分考虑了入选标准。记录并比较人口统计学、临床和生化参数。
人口统计学参数匹配，两个研究组之间未观察到显著差异。收缩压和舒张压（SBP和DBP）显示出显著差异（p<0.001）。两组之间的脉搏率无显著差异，QT/QTc均显示出统计学显著差异（p<0.001）。比较两个研究组之间的生化参数，如血清肌酐、白蛋白、球蛋白、总蛋白、血清钠、钠排泄分数、血清渗透压、香草扁桃酸，两组之间未观察到显著差异。
氨氯地平和西尼地平都是同样有效的抗高血压药物。西尼地平治疗组的血压降低幅度比氨氯地平治疗组更大，两组之间的心率无显著变化。西尼地平组的QT/QTc间期比氨氯地平组相对缩短。
